Skip to main content
Erschienen in: International Journal of Hematology 5/2020

08.08.2020 | Original Article

An analysis of oral microbial flora by T-RFLP in patients undergoing hematopoietic stem cell transplantation

verfasst von: Miho Takahashi, Masako Toyosaki, Keiko Matsui, Shinichiro Machida, Eri Kikkawa, Yoshihide Ota, Akihiro Kaneko, Yoshiaki Ogawa, Kiyoshi Ando, Makoto Onizuka

Erschienen in: International Journal of Hematology | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Even though the hematopoietic stem cell transplantation (HSCT) procedure has been improved, oral mucositis (OM) is still a severe complication of the conditioning regimen. We investigated the association between OM severity and the alteration of oral bacterial flora using 16S rRNA gene-based terminal restriction fragment length polymorphism (T-RFLP) analysis in 19 consecutive patients undergoing HSCT. Oral samples were collected at pre-transplantation, at the peak of mucositis and post-engraftment. T-RFLP profiles for each timepoint were constructed into an XY matrix, and the distances between timepoints were calculated. Patients with severe and moderate OM had larger changes in their oral bacterial flora from before HSCT to peak of mucositis than controls (p = 0.031 and 0.016, respectively). Moreover, severe mucositis was significantly associated with an extended period of fever until engraftment, high maximum C-reactive protein levels, and prolonged periods of opioid treatment and intravenous hyper-alimentation. These findings suggest that mucositis severity is associated with the magnitude of change in the oral bacterial flora. This novel finding may help advance strategies for the prevention or treatment of OM after HSCT.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001;19:2201–5.CrossRef Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001;19:2201–5.CrossRef
2.
Zurück zum Zitat Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2002;8:477–85.CrossRef Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2002;8:477–85.CrossRef
3.
Zurück zum Zitat Vokurka S, Steinerova K, Karas M, Koza V. Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2. Bone Marrow Transplant. 2009;44:601–5.CrossRef Vokurka S, Steinerova K, Karas M, Koza V. Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2. Bone Marrow Transplant. 2009;44:601–5.CrossRef
4.
Zurück zum Zitat Vagliano L, Feraut C, Gobetto G, Trunfio A, Errico A, Campani V, et al. Incidence and severity of oral mucositis in patients undergoing haematopoietic SCT[mdash]results of a multicentre study. Bone Marrow Transplant. 2011;46:727–32.CrossRef Vagliano L, Feraut C, Gobetto G, Trunfio A, Errico A, Campani V, et al. Incidence and severity of oral mucositis in patients undergoing haematopoietic SCT[mdash]results of a multicentre study. Bone Marrow Transplant. 2011;46:727–32.CrossRef
5.
Zurück zum Zitat Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100:1995–2025.CrossRef Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100:1995–2025.CrossRef
6.
Zurück zum Zitat Heimdahl A, Mattsson T, Dahllöf G, Lönnquist B, Ringdén O. The oral cavity as a port of entry for early infections in patients treated with bone marrow transplantation. Oral Surg Oral Med Oral Pathol. 1989;68:711–6.CrossRef Heimdahl A, Mattsson T, Dahllöf G, Lönnquist B, Ringdén O. The oral cavity as a port of entry for early infections in patients treated with bone marrow transplantation. Oral Surg Oral Med Oral Pathol. 1989;68:711–6.CrossRef
7.
Zurück zum Zitat Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109:820–31.CrossRef Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109:820–31.CrossRef
8.
Zurück zum Zitat Liu WT, Marsh TL, Cheng H, Forney LJ. Characterization of microbial diversity by determining terminal restriction fragment length polymorphisms of genes encoding 16S rRNA. Appl Environ Microbiol. 1997;63:4516–22.CrossRef Liu WT, Marsh TL, Cheng H, Forney LJ. Characterization of microbial diversity by determining terminal restriction fragment length polymorphisms of genes encoding 16S rRNA. Appl Environ Microbiol. 1997;63:4516–22.CrossRef
9.
Zurück zum Zitat Kim JW, Kim MG, Lee HJ, Koh Y, Kwon JH, Kim I, et al. Topical recombinant human epidermal growth factor for oral mucositis induced by intensive chemotherapy with hematopoietic stem cell transplantation: final analysis of a randomized, double-blind, placebo-controlled, phase 2 trial. PLoS ONE. 2017;12:e0168854.CrossRef Kim JW, Kim MG, Lee HJ, Koh Y, Kwon JH, Kim I, et al. Topical recombinant human epidermal growth factor for oral mucositis induced by intensive chemotherapy with hematopoietic stem cell transplantation: final analysis of a randomized, double-blind, placebo-controlled, phase 2 trial. PLoS ONE. 2017;12:e0168854.CrossRef
10.
Zurück zum Zitat Bornhäuser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol. 2012;13:1035–44.CrossRef Bornhäuser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol. 2012;13:1035–44.CrossRef
11.
Zurück zum Zitat Kuwatsuka Y, Kohno A, Terakura S, Saito S, Shimada K, Yasuda T, et al. Phase II study of dose-modified busulfan by real-time targeting in allogeneic hematopoietic stem cell transplantation for myeloid malignancy. Cancer Sci. 2012;103:1688–94.CrossRef Kuwatsuka Y, Kohno A, Terakura S, Saito S, Shimada K, Yasuda T, et al. Phase II study of dose-modified busulfan by real-time targeting in allogeneic hematopoietic stem cell transplantation for myeloid malignancy. Cancer Sci. 2012;103:1688–94.CrossRef
12.
Zurück zum Zitat Ohbayashi Y, Imataki O, Ohnishi H, Iwasaki A, Ogawa T, Inagaki N, et al. Multivariate analysis of factors influencing oral mucositis in allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2008;87:837–45.CrossRef Ohbayashi Y, Imataki O, Ohnishi H, Iwasaki A, Ogawa T, Inagaki N, et al. Multivariate analysis of factors influencing oral mucositis in allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2008;87:837–45.CrossRef
13.
Zurück zum Zitat Eilers J, Berger AM, Petersen MC. Development, testing, and application of the oral assessment guide. Oncol Nurs Forum. 1988;15:325–30.PubMed Eilers J, Berger AM, Petersen MC. Development, testing, and application of the oral assessment guide. Oncol Nurs Forum. 1988;15:325–30.PubMed
14.
Zurück zum Zitat Ringner M. What is principal component analysis? Nat Biotechnol. 2008;26:303–4.CrossRef Ringner M. What is principal component analysis? Nat Biotechnol. 2008;26:303–4.CrossRef
15.
Zurück zum Zitat Gabriel DA, Shea T, Olajida O, Serody JS, Comeau T. The effect of oral mucositis on morbidity and mortality in bone marrow transplant. Semin Oncol. 2003;30:76–83.CrossRef Gabriel DA, Shea T, Olajida O, Serody JS, Comeau T. The effect of oral mucositis on morbidity and mortality in bone marrow transplant. Semin Oncol. 2003;30:76–83.CrossRef
16.
Zurück zum Zitat Rapoport AP, Miller Watelet LF, Linder T, Eberly S, Raubertas RF, Lipp J, et al. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol. 1999;17:2446–533.CrossRef Rapoport AP, Miller Watelet LF, Linder T, Eberly S, Raubertas RF, Lipp J, et al. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol. 1999;17:2446–533.CrossRef
17.
Zurück zum Zitat Leppla L, De Geest S, Fierz K, Deschler-Baier B, Koller A. An oral care self-management support protocol (OrCaSS) to reduce oral mucositis in hospitalized patients with acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation: a randomized controlled pilot study. Support Care Cancer. 2016;24:773–82.CrossRef Leppla L, De Geest S, Fierz K, Deschler-Baier B, Koller A. An oral care self-management support protocol (OrCaSS) to reduce oral mucositis in hospitalized patients with acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation: a randomized controlled pilot study. Support Care Cancer. 2016;24:773–82.CrossRef
18.
Zurück zum Zitat Muro M, Soga Y, Higuchi T, Kataoka K, Ekuni D, Maeda Y, et al. Unusual oral mucosal microbiota after hematopoietic cell transplantation with glycopeptide antibiotics: potential association with pathophysiology of oral mucositis. Folia Microbiol (Praha). 2018;63:587–97.CrossRef Muro M, Soga Y, Higuchi T, Kataoka K, Ekuni D, Maeda Y, et al. Unusual oral mucosal microbiota after hematopoietic cell transplantation with glycopeptide antibiotics: potential association with pathophysiology of oral mucositis. Folia Microbiol (Praha). 2018;63:587–97.CrossRef
19.
Zurück zum Zitat Bayliss R, Clarke C, Oakley CM, Somerville W, Whitfield AG, Young SE. The microbiology and pathogenesis of infective endocarditis. Br Heart J. 1983;50:513–9.CrossRef Bayliss R, Clarke C, Oakley CM, Somerville W, Whitfield AG, Young SE. The microbiology and pathogenesis of infective endocarditis. Br Heart J. 1983;50:513–9.CrossRef
20.
Zurück zum Zitat Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115–26.CrossRef Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115–26.CrossRef
21.
Zurück zum Zitat Janket SJ, Baird AE, Chuang SK, Jones JA. Meta-analysis of periodontal disease and risk of coronary heart disease and stroke. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;95:559–69.CrossRef Janket SJ, Baird AE, Chuang SK, Jones JA. Meta-analysis of periodontal disease and risk of coronary heart disease and stroke. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;95:559–69.CrossRef
22.
Zurück zum Zitat Shinzato T, Saito A. The Streptococcus milleri group as a cause of pulmonary infections. Clin Infect Dis. 1995;21(3):S238–243.CrossRef Shinzato T, Saito A. The Streptococcus milleri group as a cause of pulmonary infections. Clin Infect Dis. 1995;21(3):S238–243.CrossRef
23.
Zurück zum Zitat Llambes F, Arias-Herrera S, Caffesse R. Relationship between diabetes and periodontal infection. World J Diabetes. 2015;6:927–35.CrossRef Llambes F, Arias-Herrera S, Caffesse R. Relationship between diabetes and periodontal infection. World J Diabetes. 2015;6:927–35.CrossRef
24.
Zurück zum Zitat Nishimura F, Murayama Y. Periodontal inflammation and insulin resistance–lessons from obesity. J Dent Res. 2001;80:1690–4.CrossRef Nishimura F, Murayama Y. Periodontal inflammation and insulin resistance–lessons from obesity. J Dent Res. 2001;80:1690–4.CrossRef
25.
Zurück zum Zitat Offenbacher S, Lieff S, Boggess KA, Murtha AP, Madianos PN, Champagne CM, et al. Maternal periodontitis and prematurity. Part I: Obstetric outcome of prematurity and growth restriction. Ann Periodontol. 2001;6:164–74.CrossRef Offenbacher S, Lieff S, Boggess KA, Murtha AP, Madianos PN, Champagne CM, et al. Maternal periodontitis and prematurity. Part I: Obstetric outcome of prematurity and growth restriction. Ann Periodontol. 2001;6:164–74.CrossRef
26.
Zurück zum Zitat Oral complications of cancer therapies: diagnosis, prevention, and treatment. NIH Consens Statement Online 1989;7:1-11. Oral complications of cancer therapies: diagnosis, prevention, and treatment. NIH Consens Statement Online 1989;7:1-11.
27.
Zurück zum Zitat Napenas JJ, Brennan MT, Bahrani-Mougeot FK, Fox PC, Lockhart PB. Relationship between mucositis and changes in oral microflora during cancer chemotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103:48–59.CrossRef Napenas JJ, Brennan MT, Bahrani-Mougeot FK, Fox PC, Lockhart PB. Relationship between mucositis and changes in oral microflora during cancer chemotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103:48–59.CrossRef
28.
Zurück zum Zitat Caselli E, Fabbri C, D'Accolti M, Soffritti I, Bassi C, Mazzacane S, et al. Defining the oral microbiome by whole-genome sequencing and resistome analysis: the complexity of the healthy picture. BMC Microbiol. 2020;20:120.CrossRef Caselli E, Fabbri C, D'Accolti M, Soffritti I, Bassi C, Mazzacane S, et al. Defining the oral microbiome by whole-genome sequencing and resistome analysis: the complexity of the healthy picture. BMC Microbiol. 2020;20:120.CrossRef
29.
Zurück zum Zitat Zaura E. Next-generation sequencing approaches to understanding the oral microbiome. Adv Dent Res. 2012;24:81–5.CrossRef Zaura E. Next-generation sequencing approaches to understanding the oral microbiome. Adv Dent Res. 2012;24:81–5.CrossRef
30.
Zurück zum Zitat Legert KG, Remberger M, Ringden O, Heimdahl A, Dahllof G. Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients. Support Care Cancer. 2014;22:2133–40.CrossRef Legert KG, Remberger M, Ringden O, Heimdahl A, Dahllof G. Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients. Support Care Cancer. 2014;22:2133–40.CrossRef
31.
Zurück zum Zitat Samuels BL, Bitran JD. High-dose intravenous melphalan: a review. J Clin Oncol. 1995;13:1786–99.CrossRef Samuels BL, Bitran JD. High-dose intravenous melphalan: a review. J Clin Oncol. 1995;13:1786–99.CrossRef
32.
Zurück zum Zitat Lazarus HM, Herzig RH, Graham-Pole J, Wolff SN, Phillips GL, Strandjord S, et al. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol. 1983;1:359–67.CrossRef Lazarus HM, Herzig RH, Graham-Pole J, Wolff SN, Phillips GL, Strandjord S, et al. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol. 1983;1:359–67.CrossRef
33.
Zurück zum Zitat Sonis SA. Biological approach to mucositis. J Support Oncol. 2003;2:21–322. Sonis SA. Biological approach to mucositis. J Support Oncol. 2003;2:21–322.
34.
Zurück zum Zitat Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 1998;34:39–433.CrossRef Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 1998;34:39–433.CrossRef
Metadaten
Titel
An analysis of oral microbial flora by T-RFLP in patients undergoing hematopoietic stem cell transplantation
verfasst von
Miho Takahashi
Masako Toyosaki
Keiko Matsui
Shinichiro Machida
Eri Kikkawa
Yoshihide Ota
Akihiro Kaneko
Yoshiaki Ogawa
Kiyoshi Ando
Makoto Onizuka
Publikationsdatum
08.08.2020
Verlag
Springer Singapore
Erschienen in
International Journal of Hematology / Ausgabe 5/2020
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-020-02958-y

Weitere Artikel der Ausgabe 5/2020

International Journal of Hematology 5/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.